Antalarmin

Jump to: navigation, search
Antalarmin
Antalarmin.svg
Clinical data
SynonymsAntalarmin
Legal status
Legal status
  • In general: legal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC24H34N4
Molar mass378.55 g/mol

WikiDoc Resources for Antalarmin

Articles

Most recent articles on Antalarmin

Most cited articles on Antalarmin

Review articles on Antalarmin

Articles on Antalarmin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Antalarmin

Images of Antalarmin

Photos of Antalarmin

Podcasts & MP3s on Antalarmin

Videos on Antalarmin

Evidence Based Medicine

Cochrane Collaboration on Antalarmin

Bandolier on Antalarmin

TRIP on Antalarmin

Clinical Trials

Ongoing Trials on Antalarmin at Clinical Trials.gov

Trial results on Antalarmin

Clinical Trials on Antalarmin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antalarmin

NICE Guidance on Antalarmin

NHS PRODIGY Guidance

FDA on Antalarmin

CDC on Antalarmin

Books

Books on Antalarmin

News

Antalarmin in the news

Be alerted to news on Antalarmin

News trends on Antalarmin

Commentary

Blogs on Antalarmin

Definitions

Definitions of Antalarmin

Patient Resources / Community

Patient resources on Antalarmin

Discussion groups on Antalarmin

Patient Handouts on Antalarmin

Directions to Hospitals Treating Antalarmin

Risk calculators and risk factors for Antalarmin

Healthcare Provider Resources

Symptoms of Antalarmin

Causes & Risk Factors for Antalarmin

Diagnostic studies for Antalarmin

Treatment of Antalarmin

Continuing Medical Education (CME)

CME Programs on Antalarmin

International

Antalarmin en Espanol

Antalarmin en Francais

Business

Antalarmin in the Marketplace

Patents on Antalarmin

Experimental / Informatics

List of terms related to Antalarmin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Antalarmin is a drug which acts as a CRF-1 antagonist.

Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress and drug addiction. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Chronic release of CRF and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, stomach ulcers, anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.[1]

Antalarmin is a non-peptide drug which blocks the CRF-1 receptor, and consequently reduces the release of ACTH in response to chronic stress.[2] This has been demonstrated in animals to reduce the behavioural responses to stressful situations,[3] and it is proposed that antalarmin itself, or more likely newer CRF antagonist drugs still under development,[4] could be useful for reducing the adverse health consequences of chronic stress in humans, as well as having possible uses in the treatment of conditions such as anxiety, depression and drug addiction.[5]

Results so far have had limited success, with various CRF antagonists being tested, which showed some antidepressant effects, but failed to produce an effect comparable with conventional antidepressant drugs.[6] However more positive results were seen when antalarmin was combined with an SSRI antidepressant, suggesting a potential for synergistic effect.[7] Encouraging results have also been observed using antalarmin as a potential treatment for anxiety[8][9] and stress-induced hypertension.[10]

Chronic antalarmin treatment also showed antiinflammatory effects and has been suggested as having potential uses in the treatment of inflammatory conditions such as arthritis,[11] as well as stress-induced gastrointestinal ulcers[12] and irritable bowel syndrome.[13][14]

Mixed results have been seen in research into the use of antalarmin and other CRF-1 antagonists in the treatment of drug addiction disorders. Tests of antalarmin on cocaine use in cocaine-addicted monkeys produced only slight reductions of use that were not statistically significant,[15] however in tests on cocaine-addicted rats, antalarmin did prevent dose escalation with prolonged use, suggesting that it might stabilise cocaine use and prevent it increasing over time, although without consistently reducing it.[16]

Antalarmin also showed positive effects in reducing withdrawal syndrome from chronic opioid use,[17] and significantly reduced self-administration of ethanol in ethanol-addicted rodents.[18][19][20]

See Also

External Links

Tox Battery Prepares Antalarmin for Clin Trials

References

  1. Zoumakis E, Rice KC, Gold PW, Chrousos GP. Potential uses of corticotropin-releasing hormone antagonists. Annals of the New York Acadamy of Sciences. 2006 Nov;1083:239-51.
  2. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 1996 Dec;137(12):5747-50.
  3. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. 1999 Jan;140(1):79-86.
  4. Nielsen DM, Carey GJ, Gold LH. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. European Journal of Pharmacology. 2004 Sep 19;499(1-2):135-46.
  5. McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Current Pharmaceutical Design. 1999 May;5(5):289-315.
  6. Jutkiewicz EM, Wood SK, Woods JH. The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berlin). 2005 July; 180(2): 215–223.
  7. Ducottet C, Griebel G, Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Progress in Neuropsychopharmacology and Biological Psychiatry. 2003 Jun;27(4):625-31.
  8. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Research. 2002 Oct 18;952(2):188-99.
  9. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proceedings of the National Acadamy of Sciences USA. 2000 May 23;97(11):6079-84.
  10. Briscoe RJ, Cabrera CL, Baird TJ, Rice KC, Woods JH. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Research. 2000 Oct 27;881(2):204-7.
  11. Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. Journal of Rheumatology. 2002 Jun;29(6):1252-61.
  12. Gabry KE, Chrousos GP, Rice KC, Mostafa RM, Sternberg E, Negrao AB, Webster EL, McCann SM, Gold PW. Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Molecular Psychiatry. 2002;7(5):474-83, 433.
  13. Greenwood-Van Meerveld B, Johnson AC, Cochrane S, Schulkin J, Myers DA. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterology and Motility. 2005 Jun;17(3):415-22.
  14. Martinez V, Taché Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Current Pharmaceutical Design. 2006;12(31):4071-88.
  15. Mello NK, Negus SS, Rice KC, Mendelson JH. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacology, Biochemistry and Behaviour. 2006 Dec;85(4):744-51.
  16. Specio SE, Wee S, O’Dell LE, Boutrel B, Zorrilla EP and Koob GF. CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berlin). 2008 Feb;196(3):473-482.
  17. Stinus L, Cador M, Zorrilla EP, Koob GF. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology. 2005 Jan;30(1):90-8.
  18. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biological Psychiatry. 2007 Jan 1;61(1):78-86.
  19. Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacology, Biochemistry and Behaviour. 2007 Apr;86(4):813-21.
  20. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Lê AD. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berlin). 2007 Dec;195(3):345-55.



Linked-in.jpg